|
|
|
|
|
| Trial | Studied trt | Control trt | patients | tags | ROB | Trial result | All cause death | Major bleeding |
|---|
|
| ACUITY (biva alone vs hep+aGP2b3a), 2006 NCT | bivalirudin | heparin + GP2b3a inhibitors | | | Low risk of bias | suggesting | | |
| ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 NCT | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | Low risk of bias | negative | | |
| PROTECT-TIMI 30, 2006 NCT | bivalirudin | eptifibatide + heparin | | | Exploratory | - | | |
| HERO, 1997 | bivalirudin | heparin | | | Low risk of bias | suggesting | | |
| BAT (Bittl), 1995 | bivalirudin | heparin | | | Low risk of bias | suggesting | | |
| ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 | bivalirudin | heparin + GP2b3a inhibitors | | | | suggesting | | |
| ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | | negative | | |
|
| HERO, 1997 | bivalirudin | heparin | | | Low risk of bias | suggesting | | |
|
| REPLACE-2, 2003 | bivalirudin | heparin + GP2b3a inhibitors | | | Low risk of bias | - | | |
| HORIZONS-AMI (Stone), 2008 NCT | bivalirudin | heparin + GP2b3a inhibitors | | | Risk of bias | suggesting | | |
| ACUITY (Stone) (bivalirudin alone), 2006 NCT | bivalirudin | heparin + GP2b3a inhibitors | | | Risk of bias | - | | |
| Kleiman, 2002 | bivalirudin + eptifibatide | heparin + GP2b3a inhibitors | | | Exploratory | - | | |
| ISAR-REACT 3, 2008 NCT | bivalirudin | UFH | | | Low risk of bias | - | | |
| REPLACE-1, 2004 | bivalirudin | UFH | | | Exploratory | negative | | |
| BAT (Bittl), 1995 | bivalirudin | UFH | | | Low risk of bias | suggesting | | |
| ARMYDA BIVALVE | bivalirudin | UFH | | | | - | | |
| NAPLES (Tavano), 2009 | bivalirudin | UFH plus tirofiban | | | Risk of bias | suggesting | | |
